The combination of insulin and linezolid ameliorates Staphylococcus aureus pneumonia in individuals with diabetes via the TLR2/MAPKs/NLRP3 pathway

Int J Biol Macromol. 2023 Jul 1;242(Pt 1):124750. doi: 10.1016/j.ijbiomac.2023.124750. Epub 2023 May 7.

Abstract

Diabetes mellitus (DM) complicated with Staphylococcus aureus (S. aureus) infection lacks effective treatment strategies. In this study, we found that insulin combined with linezolid has potential to deal with the thorny problem. In vitro, our drug sensitivity assay, bacterial growth curve and hemolytic tests showed that a combination of insulin and linezolid exerted good antibacterial and anti-α-hemolysin activity, CCK8 experiment, glucose content and glycogen content determination showed that the combination of insulin and linezolid increased murine macrophage survival rate and reduced the extracellular glucose level of high glucose-treated MH-S cells and intracellular glycogen level, and Western blot showed that the combination inhibited TLR2/MAPKs/NLRP3-related inflammatory pathways in MH-S cells. The results of in vivo experiments showed that the combination therapy stabilized glucose level, remained body weight, ameliorated lung injury including improving pulmonary edema and decreasing lung wet/dry weight ratio, reduced the CFUs and inflammation in the lung tissue in a mouse model of diabetes with S. aureus pneumonia, and inhibited the expression of TLR2, MAPKs and NLRP3 inflammatory pathway. Overall, the combination of insulin and linezolid as autolytic inhibitor exhibited the effects of significant antibacterial and improving glucose level in vitro and in vivo, and also has an anti-inflammation activity via the TLR2/MAPKs/NLRP3 pathway, this paves the way for new treatments for diabetes mellitus complicated with S. aureus infection.

Keywords: Autolytic inhibitor; Diabetic pneumonia; Insulin; Linezolid; Staphylococcus aureus.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Diabetes Mellitus* / drug therapy
  • Insulin / metabolism
  • Linezolid / metabolism
  • Linezolid / pharmacology
  • Linezolid / therapeutic use
  • Mice
  • NLR Family, Pyrin Domain-Containing 3 Protein / metabolism
  • Pneumonia, Staphylococcal* / drug therapy
  • Staphylococcus aureus
  • Toll-Like Receptor 2 / metabolism

Substances

  • Linezolid
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Toll-Like Receptor 2
  • Insulin
  • Anti-Bacterial Agents